Junshi Biosciences and Coherus Announce Positive Interim Overall Survival Results of CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer

    Junshi Biosciences and Coherus to meet with US FDA to discuss 1L NSCLC BLA supplement submission SHANGHAI, China and REDWOOD CITY, Calif., Dec. 13, 2021 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd. (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced positive results of an interim analysis of overall survival from the […]

    Read More

      Annual Changes to the Nasdaq Biotechnology Index

      NEW YORK, Dec. 10, 2021 (GLOBE NEWSWIRE) — Nasdaq (Nasdaq: NDAQ) today announced the results of the annual reconstitution of the Nasdaq Biotechnology Index (Nasdaq: NBI), which will become effective prior to market open on Monday, December 20, 2021. The Index is designed to track the performance of a set of securities listed on The […]

      Read More

        Annual Changes to the Nasdaq-100 Index®

        NEW YORK, Dec. 10, 2021 (GLOBE NEWSWIRE) — Nasdaq (Nasdaq: NDAQ) today announced the results of the annual reconstitution of the Nasdaq-100 Index® (Nasdaq: NDX), which will become effective prior to market open on Monday, December 20, 2021. The following six companies will be added to the Index: Airbnb, Inc. (Nasdaq: ABNB), Fortinet, Inc. (Nasdaq: […]

        Read More
        Back To Top